TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01837472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
Study: NCT03052335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam® COLON 2 Capsule
Description: The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Optical colonoscopy is the standard method for evaluating the colon
Study: NCT01739270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular brachial plexus block
Study: NCT02272816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC-10
Description: Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
Study: NCT03208491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serious games use
Description: This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care of patient
Study: NCT04095715

Intervention type: OTHER
Intervention: Haemostasis consultation
Description: Haemostasis consultation

Intervention type: BIOLOGICAL
Intervention: Standard management of patients suspected of thrombopathy
Description: Standard management of patients suspected of thrombopathy
Study: NCT00419341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Normal Immunoglobulin for Subcutaneous Administration
Study: NCT00331136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-Artesunate
Description: Once a day for 3 days
Study: NCT01876550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Calcium Cream, 2%
Description: Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactroban® Cream
Description: Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle of test product
Description: Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
Study: NCT02991170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unipolar or bipolar radiofrequency ablation+CABG
Description: Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
Study: NCT01651143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAR100842
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR100842
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SAR100842)
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT02302521

Intervention type: DEVICE
Intervention: Multiplex Sensitivity Encoding (MUSE)
Description: It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).

Intervention type: DEVICE
Intervention: Multiplex Sensitivity Encoding (MUSE)
Description: It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).

Intervention type: DEVICE
Intervention: Multiplex Sensitivity Encoding (MUSE)
Description: It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
Study: NCT03553537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100mg/m² po on day6-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg/m² po on day6-10
Study: NCT03971500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation
Study: NCT03574961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Support group
Description: Online (remote), web-based support group via private video link.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: e-Journaling placebo
Description: Online journaling activity.
Study: NCT03971500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation
Study: NCT03486353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
Study: NCT03486353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
Study: NCT04500119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator
Description: Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
Study: NCT03982277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 300 Mg Oral Capsule
Description: High dose rifampicin at 35mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 300 Mg Oral Capsule
Description: High dose rifampicin at 35mg/kg
Study: NCT04589897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manuka honey sinus rinse
Description: Will follow a modified NHS nasal rinse protocol with the addition of manuka honey

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sinus rinse
Description: will follow the standard NHS nasal rinse protocol
Study: NCT03974074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin infusion
Description: Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
Study: NCT03366363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
Study: NCT00107276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT02504372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT03177538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa and menotropin
Description: Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa and lutropin alfa
Description: Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle.
Study: NCT05282667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)
Description: A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)
Description: A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure
Study: NCT03971929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0532
Description: once daily(QD) for 4weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR placebo
Description: once daily(QD) for 4weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Description: once daily(QD) for 4weeks
Study: NCT00905190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg one time
Study: NCT01808469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Monoclonal antibody
Study: NCT01946334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anorectal manometry and high-resolution three-dimensional
Study: NCT02552576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Voncento
Description: Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
Study: NCT04476667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Psychotherapy
Description: Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
Study: NCT04231448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
Description: R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
Description: R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
Study: NCT01829568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT03433976

Intervention type: DRUG
Group type: OTHER
Intervention: spinal anesthesia
Description: spinal anesthesia for planned cesarean sections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: spinal anesthesia for planned cesarean sections
Study: NCT00331136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-Artesunate
Description: Once a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-Artesunate
Description: Once a day for 3 days
Study: NCT00632749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283 (d 1 and 15)
Description: BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283 (d1)
Description: BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
Study: NCT03091361

Intervention type: OTHER
Intervention: imaging, no intervention
Description: no intervention
Study: NCT03899350

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02814188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate Beverage
Description: 750 ml of a 13.5% carbohydrate (sucrose) beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: 750 ml of an artificially-sweetened beverage
Study: NCT03083782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban alone
Description: A single dose of 10 mg apixaban administered orally at 0H on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
Study: NCT01734096

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: Lower limbs are put in in LBNP device for one hour (-30 mbar)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: Lower limbs are put in in LBNP device for one hour (-30 mbar)
Study: NCT00632749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
Study: NCT03373448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Labrida BioClean
Description: The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.

Intervention type: OTHER
Group type: OTHER
Intervention: Titanium curettes
Description: Peri-implant pockets will be debrided using titanium curettes.
Study: NCT00168753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: IM
Study: NCT00785915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: single administration and once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration and once daily for 5 days
Study: NCT02258815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ch14.18/CHO
Description: A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year.
Study: NCT02988037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-DBT-A
Description: Adapted Dialectical Behaviour Therapy for Adolescents
Study: NCT02302521

Intervention type: DEVICE
Intervention: Multiplex Sensitivity Encoding (MUSE)
Description: It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
Study: NCT01805830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP513
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
Study: NCT01734096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
Study: NCT01805830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day